Vanderkerken K - Search Results

1

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI. Edwards CM, et al. Among authors: vanderkerken k. Int J Cancer. 2007 Apr 15;120(8):1657-63. doi: 10.1002/ijc.22478. Int J Cancer. 2007. PMID: 17230522

2

Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.

Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B. Vanderkerken K, et al. Clin Exp Metastasis. 2002;19(1):87-90. doi: 10.1023/a:1013891205989. Clin Exp Metastasis. 2002. PMID: 11918087

3

The F-actin content of multiple myeloma cells as a measure of their migration.

Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Ann N Y Acad Sci. 2002 Nov;973:124-36. doi: 10.1111/j.1749-6632.2002.tb04620.x. Ann N Y Acad Sci. 2002. PMID: 12485848

4

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Clin Exp Metastasis. 2002;19(7):583-91. doi: 10.1023/a:1020987830132. Clin Exp Metastasis. 2002. PMID: 12498387

5

Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.

Asosingh K, Vankerkhove V, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Exp Hematol. 2003 Jan;31(1):48-55. doi: 10.1016/s0301-472x(02)00970-0. Exp Hematol. 2003. PMID: 12543106 Free article.

6

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

7

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: vanderkerken k. Cancer. 2003 Feb 1;97(3 Suppl):818-24. doi: 10.1002/cncr.11125. Cancer. 2003. PMID: 12548581 Free article.

8

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: vanderkerken k. J Bone Miner Res. 2003 Mar;18(3):482-92. doi: 10.1359/jbmr.2003.18.3.482. J Bone Miner Res. 2003. PMID: 12619933 Free article.

9

Multiple myeloma biology: lessons from the 5TMM models.

Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Vanderkerken K, et al. Immunol Rev. 2003 Aug;194:196-206. doi: 10.1034/j.1600-065x.2003.00035.x. Immunol Rev. 2003. PMID: 12846816 Review.

10

Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

De Raeve HR, Asosingh K, Wisse E, Van Camp B, Van Marck E, Vanderkerken K. De Raeve HR, et al. Among authors: vanderkerken k. Virchows Arch. 2004 Oct;445(4):389-95. doi: 10.1007/s00428-004-1064-7. Epub 2004 Jun 30. Virchows Arch. 2004. PMID: 15232744

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters